RxDoctor Payments Data

Chester Griffiths, MD

Otolaryngology · Los Angeles, CANPI 1104939248

Payments from drug & device makers

$8,189in general payments, 2019–2025

Across 159 payments — averaging $51.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Merz Pharmaceuticals, LLC$901
  • Cochlear Americas$780
  • Optinose US, Inc.$713
  • Med-el Corporation$649
  • Xoran Technologies LLC$572
  • plus $3K from 15 others

What the payments were for

  • Travel & lodging$360%
  • Food & beverage$7,92597%
  • Gifts$821%
  • Entertainment$1452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,189 in reported general payments places this provider in the 85th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$253,072
Medicare patients
435
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate12$7,138
Ipratropium Bromide74$1,945
Glycopyrrolate12$1,095
Pantoprazole Sodium109$994
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav71$631
ValacyclovirValacyclovir Hcl13$541
Mupirocin64$450
Methylprednisolone67$413
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid44$366
Nortriptyline Hcl11$229
Ciprofloxacin Hcl39$219
Amitriptyline Hcl28$209
Montelukast Sodium19$176
Fluticasone Propionate15$111
Omeprazole15$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$713$7,13812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,021 otolaryngology providers in California.

Other otolaryngology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →